PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35452603-3	2022	We then use orthogonal approaches to increase binding on both the tumor and CAR-T cell sides of the immune synapse: a pharmacologic approach (azacitidine) to increase antigen density of CD70 in myeloid tumors, and an engineering approach to stabilize binding of the CAR to CD70.	Azacitidine	142-153	nuclear receptor subfamily 1 group I member 3	Homo sapiens	76-79	
33954150-0	2021	Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy.	Azacitidine	22-35	nuclear receptor subfamily 1 group I member 3	Homo sapiens	45-48	
33954150-4	2021	Priming leukemia cells with AZA increased CAR T cell/target cell conjugation and target cell killing, promoted CAR T cell divisions and expanded IFNgamma+ effector T cells in co-cultures with CD19+ leukemia Nalm-6 and Raji cells.	Azacitidine	28-31	nuclear receptor subfamily 1 group I member 3	Homo sapiens	42-45	
33954150-4	2021	Priming leukemia cells with AZA increased CAR T cell/target cell conjugation and target cell killing, promoted CAR T cell divisions and expanded IFNgamma+ effector T cells in co-cultures with CD19+ leukemia Nalm-6 and Raji cells.	Azacitidine	28-31	nuclear receptor subfamily 1 group I member 3	Homo sapiens	111-114	
33954150-11	2021	Conclusion: We propose that treatment with AZA activates OX40L/OX40 co-stimulatory signaling in CAR T cells.	Azacitidine	43-46	nuclear receptor subfamily 1 group I member 3	Homo sapiens	96-99